PE20140934A1 - Derivados de pirazol - Google Patents

Derivados de pirazol

Info

Publication number
PE20140934A1
PE20140934A1 PE2013002748A PE2013002748A PE20140934A1 PE 20140934 A1 PE20140934 A1 PE 20140934A1 PE 2013002748 A PE2013002748 A PE 2013002748A PE 2013002748 A PE2013002748 A PE 2013002748A PE 20140934 A1 PE20140934 A1 PE 20140934A1
Authority
PE
Peru
Prior art keywords
phenyl
pirazole
morfolin
carboxamide
derivatives
Prior art date
Application number
PE2013002748A
Other languages
English (en)
Inventor
Guido Galley
Cedric Ghellamallah
Roger Norcross
Philippe Pflieger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20140934A1 publication Critical patent/PE20140934A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

REFERIDO A DERIVADOS DE PIRAZOL DE LA FORMULA IA DONDE R1 ES HIDROGENO, FENILO OPCIONALMENTE SUSTITUIDO POR HALOGENO, CN, ENTRE OTROS; R2 Y R3 SON HIDROGENOS O ALQUILOS INFERIORES; Z ES UN ENLACE -CH2-, -O-. SON COMPUESTOS PREFERIDOS (S)-N-(4-(MORFOLIN-2-IL) FENIL)-5-FENIL-1H-PIRAZOL-3-CARBOXAMIDA, (S)- 1- METIL-N-(4-(MORFOLIN-2-IL) FENIL)- 5-FENIL-1H-PIRAZOL-3-CARBOXAMIDA, (S)-5-(3-CIANOFENIL)-N-(4-(MORFOLIN-2-IL) FENIL)-1H-PIRAZOL-3-CARBOXAMIDA, ENTRE OTROS. REFERIDO TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO COMPUESTO Y UN VEHICULO Y/O ADYUVANTE FARMACEUTICAMENTE ACEPTABLE, SIENDO UTIL EN EL TRATAMIENTO DE LA DEPRESION, LOS TRASTORNOS DE ANSIEDAD, EL TRASTORNO BIPOLAR, ENTRE OTROS.
PE2013002748A 2011-06-09 2012-06-06 Derivados de pirazol PE20140934A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11169217 2011-06-09

Publications (1)

Publication Number Publication Date
PE20140934A1 true PE20140934A1 (es) 2014-08-06

Family

ID=46298390

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002748A PE20140934A1 (es) 2011-06-09 2012-06-06 Derivados de pirazol

Country Status (32)

Country Link
US (1) US9073911B2 (es)
EP (1) EP2717873B1 (es)
JP (1) JP5914642B2 (es)
KR (1) KR101574905B1 (es)
CN (1) CN103596567B (es)
AR (1) AR088741A1 (es)
AU (1) AU2012266457B2 (es)
BR (1) BR112013031324B1 (es)
CA (1) CA2837255C (es)
CL (1) CL2013003484A1 (es)
CO (1) CO6801764A2 (es)
CY (1) CY1116778T1 (es)
DK (1) DK2717873T3 (es)
EA (1) EA024648B1 (es)
EC (1) ECSP13013072A (es)
ES (1) ES2546438T3 (es)
HK (1) HK1191862A1 (es)
HR (1) HRP20151077T1 (es)
IL (1) IL229549B (es)
MA (1) MA35192B1 (es)
MX (1) MX347239B (es)
MY (1) MY162160A (es)
PE (1) PE20140934A1 (es)
PL (1) PL2717873T3 (es)
PT (1) PT2717873E (es)
RS (1) RS54183B1 (es)
SG (1) SG195156A1 (es)
SI (1) SI2717873T1 (es)
TW (1) TWI440636B (es)
UA (1) UA110525C2 (es)
WO (1) WO2012168260A1 (es)
ZA (1) ZA201308939B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
ES2554843T3 (es) * 2012-01-12 2015-12-23 F. Hoffmann-La Roche Ag Derivados heterocíclicos como receptores asociados de trazas de amina (TAARs)
SG11201501958QA (en) * 2012-09-14 2015-04-29 Hoffmann La Roche Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease
EP2928473B1 (en) * 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
MA53755A (fr) * 2016-03-17 2021-08-04 Hoffmann La Roche Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité comme agonist de taar
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
CN112480005B (zh) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
CN112585128B (zh) * 2018-06-18 2023-02-21 詹森药业有限公司 作为malt1抑制剂的吡唑衍生物
KR102161787B1 (ko) * 2018-07-02 2020-10-06 한국기초과학지원연구원 수면 장애의 예방 또는 치료용 약학적 조성물
US20210395239A1 (en) 2018-09-27 2021-12-23 Hoffmann-La Roche Inc. Heterocyclyl compounds for the treatment of autoimmune disease
WO2020175957A1 (ko) * 2019-02-28 2020-09-03 주식회사 마더스제약 피라졸 아마이드 유도체 화합물 및 이의 용도
CN114008025A (zh) * 2019-05-14 2022-02-01 美特波米德有限公司 Acss2抑制剂和其使用方法
WO2023283369A1 (en) * 2021-07-08 2023-01-12 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023183444A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2024033459A1 (en) * 2022-08-12 2024-02-15 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
HUP0004557A3 (en) 1997-12-04 2002-03-28 Allergan Inc Irvine Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors and pharmaceuticals containing the same
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
CN102899314A (zh) 2011-07-29 2013-01-30 江汉大学 一种批量基因克隆的方法

Also Published As

Publication number Publication date
CL2013003484A1 (es) 2014-08-08
SI2717873T1 (sl) 2015-09-30
MX347239B (es) 2017-04-20
KR20140029517A (ko) 2014-03-10
AR088741A1 (es) 2014-07-02
HRP20151077T1 (hr) 2015-11-06
KR101574905B1 (ko) 2015-12-04
ZA201308939B (en) 2014-08-27
JP2014516066A (ja) 2014-07-07
BR112013031324B1 (pt) 2021-11-03
MA35192B1 (fr) 2014-06-02
TW201302727A (zh) 2013-01-16
HK1191862A1 (zh) 2014-08-08
EP2717873A1 (en) 2014-04-16
US9073911B2 (en) 2015-07-07
NZ617350A (en) 2016-01-29
PL2717873T3 (pl) 2015-12-31
CA2837255C (en) 2020-10-27
UA110525C2 (ru) 2016-01-12
MX2013013853A (es) 2014-01-20
DK2717873T3 (en) 2015-07-27
MY162160A (en) 2017-05-31
TWI440636B (zh) 2014-06-11
CY1116778T1 (el) 2017-03-15
CN103596567B (zh) 2016-03-16
CA2837255A1 (en) 2012-12-13
AU2012266457A1 (en) 2013-11-14
PT2717873E (pt) 2015-09-18
CN103596567A (zh) 2014-02-19
US20120316172A1 (en) 2012-12-13
RS54183B1 (en) 2015-12-31
WO2012168260A1 (en) 2012-12-13
CO6801764A2 (es) 2013-11-29
ES2546438T3 (es) 2015-09-23
BR112013031324A2 (pt) 2016-11-29
EA201391787A1 (ru) 2014-04-30
EP2717873B1 (en) 2015-07-15
IL229549A0 (en) 2014-01-30
ECSP13013072A (es) 2014-01-31
SG195156A1 (en) 2013-12-30
AU2012266457B2 (en) 2016-09-08
IL229549B (en) 2019-06-30
EA024648B1 (ru) 2016-10-31
JP5914642B2 (ja) 2016-05-11

Similar Documents

Publication Publication Date Title
PE20140934A1 (es) Derivados de pirazol
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
PE20161064A1 (es) Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20110136A1 (es) Compuestos organicos
PE20130405A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
UY29184A1 (es) Derivados de sulfonilbencimidazol
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20110061A1 (es) Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina
PE20091035A1 (es) Derivados de 2-aminopirimidina
PE20140968A1 (es) Derivados de benzamida sustituida
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20141169A1 (es) Derivados de etinilo
AR093042A1 (es) Derivados de etinilo
PE20160846A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c

Legal Events

Date Code Title Description
FG Grant, registration